透過您的圖書館登入
IP:3.133.108.241
  • 期刊
  • OpenAccess

Clozapine-associated Diabetes Mellitus and Hyperlipidemia

Clozapine引起糖尿病和高血脂症

摘要


目的:本文報告一位精神分裂症患者服用clozapine三年,產生新發作的糖尿病和高血脂症。個案報告:一位三十九歲女性慢性精神分裂症患者,曾多次精神科住院,接受多種第一代抗精神病藥物、第二代抗精神病藥物risperidone及二十次電療。這些治療並未造成患者產生糖尿病或高血脂症。之後該患者接受clozapine(每日三百毫克)三年的治療,雖其病況改善,但卻出現糖尿病和高血脂症。目前她仍需持續服用抗糖尿病及抗血脂藥物。結論:本文個案顯示以clozapine治療精神分裂病患者,需早期發現高血糖和高血脂症。

關鍵字

Clozapine 糖尿病 高血糖 高血脂

並列摘要


Objective: We report a schizophrenic woman who developed new-onset diabetes mellitus (DM) and hyperlipidemia after having taken clozapine for three years. Case Report: A 39-year-old Hakka woman with chronic schizophrenia who had multiple hospitalizations for acute psychiatric symptoms, had been treated with flupenthixol, sulpiride, clopenthixol, risperidone, flupenthixol depot injection, and 20 treatments with bilateral electroconvulsive therapy (ECT). These treatments had not caused DM or hyperlipidemia. However, her treatment was later modified and clozapine (300 mg/d) was started. Although the addition of clozapine improved her psychotic symptoms, she developed new-onset DM and hyperlipidemia three years later. At last follow up in April of 2005, she required antidiabetic and antilipid medications for controlling DM and hyperlipidemia. Conclusion: The findings of this case stress the importance of early recognition of developing hyperglycemia and hyperlipidemia when schizophrenic patients are treated with clozapine.

參考文獻


(2004).Consensus development conference on antip sy-cho-tic drugs and obesity and diabetes.J Clin Psychiatry.65,267-272.
American Psychiatric Association(1994).Diagnostic and Statistical Manual of Mental Disorders.Washington DC:
Ananth J,Venkatesh R,Burgoyne K,Gunatilake S(2002).Atypical antipsychotic drug use and diabetes.Psychother & Psychosom.71,244-254.
Chiu WC\Chang CJ(2001).Clozapine-associated diabetes mellitus: Report of two cases.Taiwanese J Psychiatry.15,71-76.
Ghaeli P,Dufresne RL,Jane JL(1996).Serum triglyceride levels in patients treated with clozapine.Am J Health Syst Pharm.53,2079-2081.

延伸閱讀